INCY Incyte Corp.

$INCY Mirum's Atebrioz approval was Friday's story. The other side of the deal is Incyte's, and it just repriced. Incyte developed zilurgisertib and licensed worldwide rights to Mirum in April: 16M upfront, up to 48M in regulatory milestones, up to 15M in commercial milestones, and mid-to-high single-digit tiered royalties on worldwide sales. Per reporting, 25M of those milestones was triggered by the approval itself. The part the headlines skipped: the FDA also handed Incyte a rare pediatric disease priority review voucher. Those are monetizable assets, sold for real money or used to speed a future filing. So Incyte outsourced FOP commercialization to Mirum's rare-disease infrastructure and kept milestone, royalty, and voucher claims. Mirum expects US availability in October; an EMA review is underway and decides how big the royalty base gets. H.C. Wainwright kept its Buy and raised the target to 152 from 150 on the approval.

$INCY Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia Weekend headline here "today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ:INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and European Union) in Australia."

$INCY This setup has my attention. Holding above the 50-day and working through a cup with handle with a 130.80 buy point. Not there yet, but definitely one I’m watching next week. 👀